-
公开(公告)号：US20060240064A9
公开(公告)日：2006-10-26
申请号：US11001422
申请日：2004-12-01
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61F2/00
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
摘要翻译： 植入物与纤维化诱导剂组合使用以诱导纤维化，否则当植入物置于动物内时可能不发生，或增加植入物和宿主组织之间的纤维化。
-
公开(公告)号：US20060240063A9
公开(公告)日：2006-10-26
申请号：US11001421
申请日：2004-12-01
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61F2/28
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
-
公开(公告)号：US20050191331A1
公开(公告)日：2005-09-01
申请号：US11001419
申请日：2004-11-30
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050181008A1
公开(公告)日：2005-08-18
申请号：US11001786
申请日：2004-12-02
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050177103A1
公开(公告)日：2005-08-11
申请号：US11006314
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
-
公开(公告)号：US20050175662A1
公开(公告)日：2005-08-11
申请号：US11000451
申请日：2004-11-29
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
-
公开(公告)号：US20050154453A1
公开(公告)日：2005-07-14
申请号：US11000461
申请日：2004-11-29
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00 , A61F2/06
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
摘要翻译： 与纤维化剂组合使用血管内装置（例如，支架，支架移植物，覆盖的支架，动脉瘤线圈，栓塞剂和药物输送导管和气囊），以便诱导当将植入物放置在动物体内时可能不会发生的纤维化 或促进器官和宿主组织之间的纤维化。 描述了组合物和方法用于治疗动脉瘤和不稳定的动脉（易受伤害的）斑块。
-
公开(公告)号：US20050149158A1
公开(公告)日：2005-07-07
申请号：US11000409
申请日：2004-11-29
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050149080A1
公开(公告)日：2005-07-07
申请号：US11001418
申请日：2004-11-30
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
摘要翻译： 植入物与抗瘢痕形成剂组合使用以抑制当植入物置于动物体内时可能发生的瘢痕形成。 该试剂可以是任何合适的抗瘢痕形成剂，例如细胞周期抑制剂，并且可以与第二药剂如抗生素联合使用。 合适的植入物包括血管内植入物，血管移植物或包裹植入物，用于血液透析通路的植入物，提供吻合连接的植入物，心室辅助植入物，假体心脏瓣膜植入物，下腔静脉滤器植入物，腹膜透析导管植入物， 中枢神经系统分流器，眼内透镜，用于青光眼引流的植入物，阴茎植入物，气管内导管，气管造口管，胃肠装置和脊柱植入物。
-
公开(公告)号：US20050148512A1
公开(公告)日：2005-07-07
申请号：US10986230
申请日：2004-11-10
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61B17/68 , A61C5/00 , A61F2/00 , A61F2/28 , A61F13/00 , A61K31/045 , A61K31/4745 , A61K31/513 , A61K31/525 , A61K31/65 , A61K31/70 , A61K31/7012 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K31/765 , A61K33/14 , A61K33/24 , A61K38/17 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/24 , A61K38/39 , A61K38/48 , A61K49/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
-
-
-
-
-
-
-
-
-
搜索结果
102 条记录 (耗时 0.204 秒)
